-
Study aim
-
Determining the effect of hemoperfusion on the improvement of symptoms of Covid-19 patients who are hospitalized with severe symptoms and the symptoms are resistant to common treatments
-
Design
-
A single-arm clinical trial without blinding and randomization on a group of patients involving at least 20 patients
-
Settings and conduct
-
Patients admitted to Imam Khomeini Hospital in Urmia with severe symptoms of COVID-19 will undergo hemoperfusion in two sessions . The variables studied in this study include para-clinical examinations ( WBC changes, renal and hepatic profile), hospitalization period , age, sex and body mass index, vital signs .after completion of two session of hemoperfusion (blood pressure, heart rate, respiration rate, arterial blood oxygen level) , pulmonary involvement severity( according to control CT- scans),and mortality will be recorded . Complications of hemoperfusion related to catheter insersion and complication occured during the hemoperfusion will be recorded too
-
Participants/Inclusion and exclusion criteria
-
Patients with severe symptoms following Covid-19 with pulmonary involvement according to CT scan more than 50%, and in patients with pulmonary involvement less than 50% who has respiratory distress, or despite receiving oxygen with a reservoir mask or non-invasive ventilation So2 is less than 88 % And the patients should not have any coagulation disorder, vasculitis, sepsis and malignancy and severe underlying disease that reduces life expectancy
-
Intervention groups
-
Patients will undergo hemoperfusion for 3 hours with a special cartridge to remove inflammatory cytokines that damage the organs through a femoral catheter. Then the patient's symptoms are evaluated if necessary Another 3-hour hemoperfusion session is performed
-
Main outcome variables
-
respiratory status based on SO2, renal and hepatic function , State of consciousness